These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 22536781

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
    Hodgkins P, Yen L, Yarlas A, Karlstadt R, Solomon D, Kane S.
    Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE.
    Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1094-102. PubMed ID: 18363894
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
    Irvine EJ, Yeh CH, Ramsey D, Stirling AL, Higgins PD.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1278-86. PubMed ID: 18808446
    [Abstract] [Full Text] [Related]

  • 8. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR, Zakko S, Gordon GL, Murthy U, Sedghi S, Pruitt R, Merchant K, Bortey E, Forbes WP.
    Aliment Pharmacol Ther; 2012 Jul 01; 36(2):126-34. PubMed ID: 22617015
    [Abstract] [Full Text] [Related]

  • 9. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 10. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE.
    Gastroenterology; 2007 Jan 01; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [Abstract] [Full Text] [Related]

  • 11. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.
    Yarlas A, Yen L, Hodgkins P.
    Qual Life Res; 2015 Mar 01; 24(3):671-83. PubMed ID: 25193617
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 01; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 15. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M.
    Gut; 2005 Jul 01; 54(7):960-5. PubMed ID: 15951542
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP.
    Am J Gastroenterol; 2009 Jun 01; 104(6):1452-9. PubMed ID: 19491859
    [Abstract] [Full Text] [Related]

  • 17. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM, Kushkuley S, Barrett JA, Oster G.
    Aliment Pharmacol Ther; 2012 Aug 01; 36(3):248-56. PubMed ID: 22690748
    [Abstract] [Full Text] [Related]

  • 18. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
    Yarlas A, D'Haens G, Willian MK, Teynor M.
    Inflamm Bowel Dis; 2018 Jan 18; 24(2):450-463. PubMed ID: 29361097
    [Abstract] [Full Text] [Related]

  • 19. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Bianchi Porro G.
    Ital J Gastroenterol Hepatol; 1999 Nov 18; 31(8):677-84. PubMed ID: 10730559
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB, Wedel MK, Xia S, Baker BF.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1403-13. PubMed ID: 16669955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.